Evogene

NASDAQ EVGN
$0.69 -0.01 -1.95%
Today share price
Israel
Sector: Healthcare Industry: Biotechnology
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Rating Finrange

Index: 22 %
Market cap

Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.

34.73M
EV

Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

25.18M
Beta

Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.

0.78
Shares

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.

50.58M
YTD

Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.

-18.26 %

Upcoming events Evogene

All events
No upcoming events scheduled

Stock chart Evogene

Stock analysis Evogene

Indicator Company Industry
P/E (LTM)

Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.

More
-1.41 16.17
P/BV (LTM)

Shows the ratio of the market price of the share to the current book value.

More
2.88 4.32
EV/EBITDA (LTM)

Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.

More
-1.05 8.89
Net Debt/EBITDA (LTM)

A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.

More
0.40 0.64
ROE (LTM)

Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.

More
-204.01 4.05

Price change Evogene per year

2.38$ 10.24$
Min Max

Summary analysis Evogene

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure Evogene

Revenue and net income Evogene

All parameters

About company Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through big data and artificial intelligence, designed to computationally discover and uniquely guide the development of life-science products based on microbes, small molecules, and genetic elements. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer; and through its subsidiary, Canonic Ltd., has a collaboration agreement with Cannbit Ltd., a subsidiary of Tikun Olam-Cannbit Ltd. for the development of novel medical cannabis products. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.
Address:
13 Gad Feinstein Street, Rehovot, Israel, 7414002
Company name: Evogene
Issuer ticker: EVGN
ISIN: IL0011050551
Country: Israel
Exchange: NASDAQ
Currency: $
IPO date: 2008-03-05
Sector: Healthcare
Industry: Biotechnology
Site: https://www.evogene.com

On which stock exchange are Evogene (EVGN) stocks traded?

Evogene (EVGN) stocks are traded on NASDAQ.

What is the ticker of Evogene stocks (EVGN)?

The stock ticker of Evogene’s stocks or in other words, the code is EVGN. The stocks are currently listed on the NASDAQ exchange.

In which sector and industry does Evogene (EVGN) operate?

According to the GICS (Global Industry Classification Standard) classification developed jointly by MSCI and Standard & Poor's, Evogene (EVGN) belongs to the «Healthcare» sector and the «Biotechnology» industry.

In what currency are Evogene (EVGN) stocks traded?

Evogene (EVGN) stocks are traded on the NASDAQ exchange in dollars.

What is the price of Evogene (EVGN) stocks today?

The current price of Evogene stocks on 13.05.2024 is 0.6866 dollars. per share.

What is the dynamics of Evogene (EVGN) stocks from the beginning of the year?

Evogene (EVGN) quotes have increased by -21.17% from the beginning of the year up to 0.6866 dollars. per 1 stocks.

How much did Evogene (EVGN) stocks increase in мае 2024?

This month Evogene (EVGN) quotes have increased by -4.05% to 0.6866 dollars. per share.

How much are Evogene (EVGN) stocks worth?

Today, on October, 13.05.2024 Evogene’s (EVGN) stocks cost 0.6866 dollars..

What is the market capitalization of Evogene (EVGN)?

Capitalization is the market value of Evogene (EVGN) is calculated as the number of issued stocks multiplied on the current quotation price. Thus, on 13.05.2024, the market capitalization of Evogene (EVGN) is estimated at about 34731584 dollars.